drugset / Trial / NCT00089258
Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
Phase 2
Completed
74 enrolled
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI) · collab
Open-labelTreatment
Summary
RATIONALE: Monoclonal antibodies, such as monoclonal antibody 3F8, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Beta-glucan, isotretinoin, and sargramostim may increase the effectiveness of monoclonal antibody 3F8 by making tumor cells more sensitive to the monoclonal antibody. Combining different types of biological therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving beta-glucan, isotretinoin, and sargramostim together with monoclonal antibody 3F8 works in treating patients with neuroblastoma that has not responded to previous treatment.
Timeline
- Start
- 2004-07
- Primary completion
- 2006-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 3F8 | Monoclonal antibody | — | Intravenous |
| Subject | Isotretinoin | Other / unclassified | — | Oral |
| Subject | beta-glucan | Other / unclassified | — | Oral |
| Subject | sargramostim | Protein / enzyme biologic | — | Subcutaneous |